B-Lymphocyte Depletion With Rituximab and β-Cell Function: Two-Year Results

OBJECTIVE: We previously reported that selective depletion of B-lymphocytes with rituximab, an anti-CD20 monoclonal antibody, slowed decline of β-cell function in recent-onset type 1 diabetes mellitus (T1DM) at 1 year. Subjects were followed further to determine whether there was persistence of effe...

Descripción completa

Detalles Bibliográficos
Autores principales: Pescovitz, Mark D., Greenbaum, Carla J., Bundy, Brian, Becker, Dorothy J., Gitelman, Stephen E., Goland, Robin, Gottlieb, Peter A., Marks, Jennifer B., Moran, Antoinette, Raskin, Philip, Rodriguez, Henry, Schatz, Desmond A., Wherrett, Diane K., Wilson, Darrell M., Krischer, Jeffrey P., Skyler, Jay S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2014
Materias:
Emerging Technologies and Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3898764/
https://www.ncbi.nlm.nih.gov/pubmed/24026563
http://dx.doi.org/10.2337/dc13-0626

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3898764/
https://www.ncbi.nlm.nih.gov/pubmed/24026563
http://dx.doi.org/10.2337/dc13-0626

Ejemplares similares